Takeda Research & Development and COVID-19

March 25, 2020

Takeda R&D has aligned around a set of guiding principles that inform our decisions and actions, in response to the COVID-19 pandemic:

  1. Ensure the safety of our employees, our families and our communities
  2. Ensure the safety of patients
  3. Stay focused and advance our priority R&D programs
  4. Uphold Takeda’s commitment to being socially responsible, and
  5. Focus on priorities in our research laboratories and vivariums, maintaining the highest standards

 

Takeda & Clinical Trial Activities
As always, Takeda is committed to ensuring the integrity of our global clinical trials while safeguarding the many patients, healthcare providers, employees and other partners who participate in our studies. We are dedicated to protecting global public health and appreciate the extraordinary circumstances under which investigators and site staff around the world are operating clinical studies while managing the additional burdens caused by COVID-19.

Due to the global impact of COVID-19, Takeda is placing a temporary pause on the initiation of new studies with the exception of TAK-888 our investigational plasma-derived therapy for COVID-19. For already ongoing studies we will temporarily pause the activation of new study sites and new patient enrollment with a small number of exceptions. This is a short-term action and we are preparing for --  and look forward to, resuming all activities as quickly as possible as the COVID-19 situation resolves around the world.

 

Given the fluidity of the pandemic, we are evaluating each trial on a fit-for-purpose basis taking into consideration the varying impact of COVID-19 in different regions of the world. Where possible, Takeda is working to quickly and creatively implement solutions such as direct to patient delivery of study medicines and the re-evaluation of trial design to account for potential disruptions. We are also in the process of assessing and building out digital technologies to enable remote monitoring of patients enrolled in clinical trials.